Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Jessica Skarzynski
As researchers recently discovered, outcomes for patients with diffuse large B-cell lymphoma are just as good when the number of chemotherapy cycles is reduced.
Brielle Benyon
A web-based intervention may help reduce harmful UV exposure and skin cancer risk in young adults, according to recent research.
Gina Columbus
The FDA has approved Ultomiris (ravulizumab-cwvz) as an injection treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that leads to hemolysis.
Beth Fand Incollingo
The investigational targeted drug zanubrutinib (BGB-3111) appeared to be highly active, inducing an overall response rate of 83.5 percent in patients with relapsed/refractory mantle cell lymphoma, who were treated in a single-arm, open-label, multicenter, phase 2 trial.
 
Kristie L. Kahl
The Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients aged 2 or older.
Brielle Benyon
The Food and Drug Administration approved Asparlas (calaspargase pegol-mknl) as a component of a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia (ALL), according to the agency.
Brielle Benyon
This is the first approval of a PARP inhibitor as a first-line maintenance treatment for BRCA-mutant gynecologic cancers.
Kristie L. Kahl
The Food and Drug Administration (FDA) granted accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to the agency.
Brielle Benyon
The Food and Drug Administration (FDA) approved BRACAnalysis CDx to be used to identify patients with advanced ovarian cancer who have germline BRCA mutations and are eligible for first line treatment with Lynparza (olaparib) after responding to platinum-based chemotherapy.
Kristie L. Kahl
The combination use of Imbruvica (ibrutinib) with Rituxan (rituximab) significantly improved survival outcomes compared with standard of care in younger patients with chronic lymphocytic leukemia (CLL).
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other